Anmeldung erfolgt in Kürze...
Details werden geladen...
Press Release: Novartis Fabhalta(R) (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney functio... | 17.07.26 | finanzen.ch
-- Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 -- Clinically meaningful improveme...
Ähnliche Seiten
Press Release: Novartis Fabhalta(R) (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney functio... | 17.07.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/press-release-novartis-fabhaltar-iptacopan-receives-fda-traditional-approval-as-first-and-only-complement-inhibitor-to-significantly-slow-kidney-functio--1036334571
Novartis Pharma AG: Novartis Fabhalta (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
https://www.finanznachrichten.de/nachrichten-2026-07/69051745-novartis-pharma-ag-novartis-fabhalta-iptacopan-receives-fda-traditional-approval-as-first-and-only-complement-inhibitor-to-significantly-slow-kidne-399.htm
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN | The Manila Times
https://www.manilatimes.net/2026/07/17/tmt-newswire/globenewswire/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-as-first-and-only-complement-inhibitor-to-significantly-slow-kidney-function-decline-in-primary-igan/2386326